基本的商品短缺會使癌症療程停下來，病人的生存就會受到影響
這是一篇調查廠商們對於缺貨的反應
以及醫師們對於缺貨以後的抱怨XD
以及醫師們對於缺貨以後的抱怨XD
整篇沒有重點....(挑錯文了)
只有一些單字比較少看到的感覺
這裡講的是生理食鹽水(NS)缺貨
看到這裡客官一定想為什麼NS不是鹽巴泡的怎麼也會缺貨
其實不是NS本身缺貨，而是裝載NS的容器的一個外接頭缺貨...
只有一些單字比較少看到的感覺
這裡講的是生理食鹽水(NS)缺貨
看到這裡客官一定想為什麼NS不是鹽巴泡的怎麼也會缺貨
其實不是NS本身缺貨，而是裝載NS的容器的一個外接頭缺貨...
單字
saga (n.) 冒險故事
survey (n.) 調查
pursue (v.) 追求、探尋
distributor (n.) 經銷商
attempt (v.) 嘗試
inventory (n.)庫存
commodity (n.) 商品
halt (v.) 停止
plaguing 困擾著
depict (v.) 描述
IV Fluid Shortages Hit Oncology Practices
In the latest chapter in the ongoing saga of drug shortages, certain fluids used in intravenous (IV) therapy are now in short supply. This shortage already appears to be affecting community oncology practices.
In a survey of 66 practices just released by the Community Oncology Alliance (COA), 53% reported having received warnings from multiple manufacturers and having been affected by the shortage of IV fluids.
Additionally, 44% of the practices surveyed have adjusted how and when fluids are used, are pursuing additional distributors to meet their needs, and/or are attempting to create excess inventory to mitigate future shortages.
In contrast, only 15% reported limited awareness of the problem, and less than 2% said that they were not concerned at all.
"The use of IV fluids during chemotherapy is standard practice," said Mark Thompson, MD, COA president and a practicing oncologist at the Zangmeister Cancer Center in Columbus, Ohio, in a statement. "Such a basic commodity in short supply, causing oncologists to modify treatment protocols, could halt our progress in fighting cancer. Patients' lives would be affected."
The serious shortage of certain IV fluids, particularly sodium chloride injection 0.9% (IV saline) in 1000 mL bags, is the latest in a series of drug shortages that have been plaguing the nation for some time now. A shortage of critical drugs has been an ongoing issue for almost a decade, and oncology has been hit particularly hard by it. In a survey reported late last year, 82.7% of oncologists said they were unable to prescribe their preferred chemotherapy agent because of shortages at least once in previous 6 months.
The drugs most commonly reported to be in short supply were leucovorin (reported by 66.4% of oncologists surveyed), liposomal doxorubicin (reported by 61.7%), fluorouracil (reported by 18.7%), bleomycin (reported by 17.3%), and cytarabine (reported by 16.4%).
Common IV solutions have now been added to the list.
Most responders to the COA survey indicated that they were aware of the shortage, were concerned about it, and had initiated practice changes or adjustments. Conversely, only 14% of the practices surveyed have made no changes to address current or future shortages.
Almost half (44%) reported that they are acutely concerned about a potential shortage of IV fluids. One response described a practice "trying to order what we can" so as not to run out.
Another response depicted a situation in which "our distributor has guaranteed they are prioritizing clients' quantities by what your history is, so people cannot get on the band wagon and take away from their loyal customers."
One response noted that "the prices are sometimes twice what I normally pay when I find product."
Another said that one supplier has instituted a significant price increase on a per case basis. "Cost is astronomical and unsustainable."
FDA Involvement
In January, the US Food and Drug Administration (FDA) issued a statement explaining that they are aware of the shortage of IV solutions, particularly 0.9% sodium chloride injection. The agency stated that they are working with Baxter Healthcare Corp, B. Braun Medical Inc., and Hospira Inc., which manufacture these products, to help preserve the supply.
In a Medscape interview, Capt. Valerie Jensen, RPh, associate director of the drug shortages program at the FDA Center for Drug Evaluation and Research, explained that the FDA "cannot require a company to make any amount of the product, and we cannot require a company to increase production."
However, she noted, the FDA has been working very closely with all the firms making IV fluids, and "they are responding well."
In the latest chapter in the ongoing saga of drug shortages, certain fluids used in intravenous (IV) therapy are now in short supply. This shortage already appears to be affecting community oncology practices.
In a survey of 66 practices just released by the Community Oncology Alliance (COA), 53% reported having received warnings from multiple manufacturers and having been affected by the shortage of IV fluids.
Additionally, 44% of the practices surveyed have adjusted how and when fluids are used, are pursuing additional distributors to meet their needs, and/or are attempting to create excess inventory to mitigate future shortages.
In contrast, only 15% reported limited awareness of the problem, and less than 2% said that they were not concerned at all.
"The use of IV fluids during chemotherapy is standard practice," said Mark Thompson, MD, COA president and a practicing oncologist at the Zangmeister Cancer Center in Columbus, Ohio, in a statement. "Such a basic commodity in short supply, causing oncologists to modify treatment protocols, could halt our progress in fighting cancer. Patients' lives would be affected."
The serious shortage of certain IV fluids, particularly sodium chloride injection 0.9% (IV saline) in 1000 mL bags, is the latest in a series of drug shortages that have been plaguing the nation for some time now. A shortage of critical drugs has been an ongoing issue for almost a decade, and oncology has been hit particularly hard by it. In a survey reported late last year, 82.7% of oncologists said they were unable to prescribe their preferred chemotherapy agent because of shortages at least once in previous 6 months.
The drugs most commonly reported to be in short supply were leucovorin (reported by 66.4% of oncologists surveyed), liposomal doxorubicin (reported by 61.7%), fluorouracil (reported by 18.7%), bleomycin (reported by 17.3%), and cytarabine (reported by 16.4%).
Common IV solutions have now been added to the list.
Most responders to the COA survey indicated that they were aware of the shortage, were concerned about it, and had initiated practice changes or adjustments. Conversely, only 14% of the practices surveyed have made no changes to address current or future shortages.
Almost half (44%) reported that they are acutely concerned about a potential shortage of IV fluids. One response described a practice "trying to order what we can" so as not to run out.
Another response depicted a situation in which "our distributor has guaranteed they are prioritizing clients' quantities by what your history is, so people cannot get on the band wagon and take away from their loyal customers."
One response noted that "the prices are sometimes twice what I normally pay when I find product."
Another said that one supplier has instituted a significant price increase on a per case basis. "Cost is astronomical and unsustainable."
FDA Involvement
In January, the US Food and Drug Administration (FDA) issued a statement explaining that they are aware of the shortage of IV solutions, particularly 0.9% sodium chloride injection. The agency stated that they are working with Baxter Healthcare Corp, B. Braun Medical Inc., and Hospira Inc., which manufacture these products, to help preserve the supply.
In a Medscape interview, Capt. Valerie Jensen, RPh, associate director of the drug shortages program at the FDA Center for Drug Evaluation and Research, explained that the FDA "cannot require a company to make any amount of the product, and we cannot require a company to increase production."
However, she noted, the FDA has been working very closely with all the firms making IV fluids, and "they are responding well."
沒有留言:
張貼留言